Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Early opportunity to invest in a Nevada lithium project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News HilleVax Inc. HLVX

Healthcare Biotechnology
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:HLVX)

Fundamentals Snapshot (NDAQ:HLVX)

Current News (NDAQ:HLVX)

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire May 12, 2023

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

GlobeNewswire May 9, 2023

HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

GlobeNewswire April 25, 2023

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

GlobeNewswire March 17, 2023

HilleVax Announces Executive Management Appointments and Promotions

GlobeNewswire January 9, 2023

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

GlobeNewswire December 5, 2022

HilleVax to Participate in November Investor Conferences

GlobeNewswire November 10, 2022

HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

GlobeNewswire November 10, 2022
View More News ››

Opinion & Analysis (NDAQ:HLVX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:HLVX)

Be the first to post on this bullboard.

Taranis Resources Inc.

Taranis Resources Inc.

Taranis Resources Inc is a Canada based exploration stage company. The business activity of the group is operated through one ...
View More »